140,000 Shares in Catalent, Inc. (NYSE:CTLT) Purchased by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas purchased a new position in Catalent, Inc. (NYSE:CTLT) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 140,000 shares of the company’s stock, valued at approximately $8,480,000. Oddo BHF Asset Management Sas owned approximately 0.08% of Catalent at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Athos Capital Ltd acquired a new position in Catalent in the 3rd quarter worth about $6,009,000. Dynamic Technology Lab Private Ltd acquired a new position in Catalent in the third quarter worth approximately $1,131,000. State Street Corp raised its position in Catalent by 1.5% during the third quarter. State Street Corp now owns 7,451,135 shares of the company’s stock valued at $451,315,000 after acquiring an additional 113,095 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in Catalent by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock valued at $24,550,000 after acquiring an additional 14,373 shares during the last quarter. Finally, Quest Partners LLC boosted its holdings in Catalent by 289.8% in the third quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock worth $2,986,000 after purchasing an additional 36,652 shares in the last quarter.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is owned by corporate insiders.

Catalent Stock Performance

CTLT opened at $63.07 on Friday. Catalent, Inc. has a 1 year low of $37.03 and a 1 year high of $63.25. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The business’s 50-day moving average price is $60.25 and its two-hundred day moving average price is $58.91.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. Catalent’s revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.10) EPS. On average, equities research analysts anticipate that Catalent, Inc. will post 0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CTLT. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a report on Tuesday. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.